ORIGINAL RESEARCH
Published on 18 Dec 2024
Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC
doi 10.3389/fphar.2024.1464852
- 176 views
2,877
Total Downloads
9,753
Total Views and Downloads
Select the journal/section where you want your idea to be submitted:
ORIGINAL RESEARCH
Published on 18 Dec 2024
REVIEW
Published on 25 Nov 2024
REVIEW
Published on 16 Sep 2024
REVIEW
Published on 06 Sep 2024
ORIGINAL RESEARCH
Published on 04 Sep 2024
CASE REPORT
Published on 29 Aug 2024
REVIEW
Published on 26 Aug 2024
ORIGINAL RESEARCH
Published on 23 Jul 2024
REVIEW
Published on 22 Jul 2024
Frontiers in Oncology
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Select the journal/section where you want your idea to be submitted: